SURMOUNT-4: RCT data exploring tirzepatide for maintaining weight loss in people with obesity
In this medfyle
Obesity is a chronic disease, and it is often difficult to maintain weight-loss efforts over time. New data from SURMOUNT-4 support the idea that obesity is a chronic metabolic condition that requires long-term therapy for most people.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original Article:
Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.2023.24945. PMID: 38078870; PMCID: PMC10714284.
The summary content was prepared by Marie Farrow for Medfyle, and reviewed by Marco Comoglio, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
